Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Lymphoma, Non-Hodgkin 1Fanconi Anemia 1Colorectal Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 65Cisplatin 42Cetuximab 36Radiotherapy 28Nivolumab 26Paclitaxel 22Carboplatin 22Docetaxel 20durvalumab 14Radiotherapy, Intensity-Modulated 12Fluorouracil 12Cyclophosphamide 11tremelimumab 9Gemcitabine 9Ipilimumab 8fludarabine 7avelumab 7Erlotinib Hydrochloride 7toripalimab 6epacadostat 6cemiplimab 6Radiosurgery 6Interleukin-2 6Capecitabine 6Bevacizumab 6spartalizumab 5Celecoxib 5zalutumumab 4tislelizumab 4fludarabine phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × SRA737 × Head & Neck × Clear all
NCT02797964 2023-06-18

A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer

Sierra Oncology LLC - a GSK company

Phase 1/2 Completed
107 enrolled 20 charts
Classical hematologyGastrointestinalHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Fanconi Anemia, Lymphoma, Non-Hodgkin, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡